FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2133324470> ?p ?o ?g. }

• W2133324470 endingPage "R25" @default.
• W2133324470 startingPage "R25" @default.
• W2133324470 abstract "Management of osteoarthritis (OA) includes the use of non-pharmacological and pharmacological therapies. Although walking is commonly recommended for reducing pain and increasing physical function in people with OA, glucosamine sulphate has also been used to alleviate pain and slow the progression of OA. This study evaluated the effects of a progressive walking program and glucosamine sulphate intake on OA symptoms and physical activity participation in people with mild to moderate hip or knee OA.Thirty-six low active participants (aged 42 to 73 years) were provided with 1500 mg glucosamine sulphate per day for 6 weeks, after which they began a 12-week progressive walking program, while continuing to take glucosamine. They were randomized to walk 3 or 5 days per week and given a pedometer to monitor step counts. For both groups, step level of walking was gradually increased to 3000 steps/day during the first 6 weeks of walking, and to 6000 steps/day for the next 6 weeks. Primary outcomes included physical activity levels, physical function (self-paced step test), and the WOMAC Osteoarthritis Index for pain, stiffness and physical function. Assessments were conducted at baseline and at 6-, 12-, 18-, and 24-week follow-ups. The Mann Whitney Test was used to examine differences in outcome measures between groups at each assessment, and the Wilcoxon Signed Ranks Test was used to examine differences in outcome measures between assessments.During the first 6 weeks of the study (glucosamine supplementation only), physical activity levels, physical function, and total WOMAC scores improved (P < 0.05). Between the start of the walking program (Week 6) and the final follow-up (Week 24), further improvements were seen in these outcomes (P < 0.05) although most improvements were seen between Weeks 6 and 12. No significant differences were found between walking groups.In people with hip or knee OA, walking a minimum of 3000 steps (approximately 30 minutes), at least 3 days/week, in combination with glucosamine sulphate, may reduce OA symptoms. A more robust study with a larger sample is needed to support these preliminary findings.Australian Clinical Trials Registry ACTRN012607000159459." @default.
• W2133324470 created "2016-06-24" @default.
• W2133324470 creator A5006264568 @default.
• W2133324470 creator A5006593989 @default.
• W2133324470 creator A5042161161 @default.
• W2133324470 date "2010-01-01" @default.
• W2133324470 modified "2023-10-06" @default.
• W2133324470 title "Efficacy of a progressive walking program and glucosamine sulphate supplementation on osteoarthritic symptoms of the hip and knee: a feasibility trial" @default.
• W2133324470 cites W1455832582 @default.
• W2133324470 cites W1531941697 @default.
• W2133324470 cites W1573234480 @default.
• W2133324470 cites W1963877193 @default.
• W2133324470 cites W1965025562 @default.
• W2133324470 cites W1968993613 @default.
• W2133324470 cites W1973448466 @default.
• W2133324470 cites W1980128180 @default.
• W2133324470 cites W1987199959 @default.
• W2133324470 cites W1991720524 @default.
• W2133324470 cites W1992995060 @default.
• W2133324470 cites W2001229982 @default.
• W2133324470 cites W2020491014 @default.
• W2133324470 cites W2025283159 @default.
• W2133324470 cites W2025298047 @default.
• W2133324470 cites W2031212518 @default.
• W2133324470 cites W2041797327 @default.
• W2133324470 cites W2051469487 @default.
• W2133324470 cites W2071889757 @default.
• W2133324470 cites W2072194882 @default.
• W2133324470 cites W2073243120 @default.
• W2133324470 cites W2074339153 @default.
• W2133324470 cites W2076201675 @default.
• W2133324470 cites W2079058802 @default.
• W2133324470 cites W2081268315 @default.
• W2133324470 cites W2081388825 @default.
• W2133324470 cites W2081644697 @default.
• W2133324470 cites W2095935951 @default.
• W2133324470 cites W2103540689 @default.
• W2133324470 cites W2106059946 @default.
• W2133324470 cites W2106903173 @default.
• W2133324470 cites W2115127070 @default.
• W2133324470 cites W2115506640 @default.
• W2133324470 cites W2115805053 @default.
• W2133324470 cites W2121126478 @default.
• W2133324470 cites W2129875336 @default.
• W2133324470 cites W2130513475 @default.
• W2133324470 cites W2132960480 @default.
• W2133324470 cites W2133915381 @default.
• W2133324470 cites W2136937654 @default.
• W2133324470 cites W2141882480 @default.
• W2133324470 cites W2146251890 @default.
• W2133324470 cites W2146518611 @default.
• W2133324470 cites W2150639626 @default.
• W2133324470 cites W2151332754 @default.
• W2133324470 cites W2153862724 @default.
• W2133324470 cites W2168404153 @default.
• W2133324470 cites W2188717473 @default.
• W2133324470 cites W2274722622 @default.
• W2133324470 cites W2485979921 @default.
• W2133324470 cites W2610860323 @default.
• W2133324470 cites W626450939 @default.
• W2133324470 cites W2169805122 @default.
• W2133324470 cites W2183032512 @default.
• W2133324470 doi "https://doi.org/10.1186/ar2932" @default.
• W2133324470 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2875659" @default.
• W2133324470 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20152042" @default.
• W2133324470 hasPublicationYear "2010" @default.
• W2133324470 type Work @default.
• W2133324470 sameAs 2133324470 @default.
• W2133324470 citedByCount "32" @default.
• W2133324470 countsByYear W21333244702012 @default.
• W2133324470 countsByYear W21333244702013 @default.
• W2133324470 countsByYear W21333244702014 @default.
• W2133324470 countsByYear W21333244702015 @default.
• W2133324470 countsByYear W21333244702016 @default.
• W2133324470 countsByYear W21333244702017 @default.
• W2133324470 countsByYear W21333244702018 @default.
• W2133324470 countsByYear W21333244702019 @default.
• W2133324470 countsByYear W21333244702021 @default.
• W2133324470 countsByYear W21333244702022 @default.
• W2133324470 crossrefType "journal-article" @default.
• W2133324470 hasAuthorship W2133324470A5006264568 @default.
• W2133324470 hasAuthorship W2133324470A5006593989 @default.
• W2133324470 hasAuthorship W2133324470A5042161161 @default.
• W2133324470 hasBestOaLocation W21333244701 @default.
• W2133324470 hasConcept C126322002 @default.
• W2133324470 hasConcept C142724271 @default.
• W2133324470 hasConcept C168563851 @default.
• W2133324470 hasConcept C1862650 @default.
• W2133324470 hasConcept C204787440 @default.
• W2133324470 hasConcept C2776164576 @default.
• W2133324470 hasConcept C2779070388 @default.
• W2133324470 hasConcept C2779279471 @default.
• W2133324470 hasConcept C2779286237 @default.
• W2133324470 hasConcept C3020255362 @default.
• W2133324470 hasConcept C71924100 @default.
• W2133324470 hasConcept C99508421 @default.
• W2133324470 hasConceptScore W2133324470C126322002 @default.
• W2133324470 hasConceptScore W2133324470C142724271 @default.

• next